Oncology Drug Approval - Accelerated

Bridging the gap between biomarkers and In Vitro Companion Diagnostics

Overview

Mission Statement
MolecularMD provides innovative and reliable molecular diagnostic solutions that improve and advance personalized medicine for cancer patients.

Founders Dr. Brian Druker (lead clinical investigator for imatinib and Director of the OHSU Knight Cancer Institute) and Sheridan Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) had one vision: To improve patient care by providing precise, standardized molecular testing for new oncology drugs.

Our initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS).

With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. These services and products are used to select, monitor and manage response for patients treated with molecularly-targeted cancer therapies in alignment with clinical development and regulatory approval strategies. We are dedicated to delivering diagnostic solutions that support the approval and clinical adoption of oncology medicines.

Oncology Thought Leaders Series:
Brian Druker, MD speaks on the value of
companion diagnostics in patient outcomes